Evaluation the efficay of q10 on Neurological Complication in Multiple Myeloma

Evaluation the efficacy of Coenzyme Q10 on Bortozomib and Thalidomide induced Neurotoxicity(Neuropathy) in patient with Multiple Myeloma malignancy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016110626390N6

Enrollment

Registered

2016-11-22

Start date

2016-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma. Multiple myeloma

Interventions

Intervention 1: Patients in intervention group will recieve Q10 at dose of 200 millgram dialy for 3 months. Q10 purchase from Livaar Company in 100 mg and patient will recieve 2 times a day. Intervent

Treatment - Other

Placebo

Patients in intervention group will recieve Q10 at dose of 200 millgram dialy for 3 months. Q10 purchase from Livaar Company in 100 mg and patient will recieve 2 times a day

Patients in control group will recieve 2 times a day of wheat flour for 3 months.

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 30 and 70 years old; normal function for liver and kidney; multiple myeloma diagnosed patients. Exclusion criteria: chemotherapy; neuropathy due to diabetes, HIV, alcohol abuse, thyroid dysfunction; congenital neurological dysfunction; dietary supplement 2 months before the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
A-SAP, sensory action potential amplitude. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.;SCV, sensory conduction velocity. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.;DML, distal motor latency. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.;A-CMAP, amplitude of compound muscle action potential. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.;MCV, motor conduction velocity. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.	—

Measure

Time frame

A-SAP, sensory action potential amplitude. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.;SCV, sensory conduction velocity. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.;DML, distal motor latency. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.;A-CMAP, amplitude of compound muscle action potential. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.;MCV, motor conduction velocity. Timepoint: before intervention and 3 months after that. Method of measurement: Electromyography.

—

Secondary

Measure	Time frame
Weight. Timepoint: Before intervention and 3 months after that. Method of measurement: Sensitive Balance.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Ahmadzadeh

Ahwaz Jundishapoor University of Medical Science

m_pedram@gmail.com+98 61 3374 3285

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026